Lemborexant (Dayvigo): Independent Evidence on Insomnia, Side Effects & Risks

by
Key takeaways
  • Lemborexant (Dayvigo) is an orexin receptor antagonist sleeping pill discovered in-house by Eisai, a Japanese company. The US FDA approved it on 20 December 2019 and Japan on 23 January 2020 (FDA approval letter, Eisai 2020).
  • It is not licensed in the UK or EU. There is no UK Medicines Compendium listing, and the EMA has approved only one orexin antagonist, daridorexant (EMC search, Actas Esp Psiquiatr 2024).
  • The publicly funded Lancet 2022 network meta-analysis rated lemborexant, together with eszopiclone, as having "a favorable profile". It was one of only two drugs that beat placebo in long-term treatment (SMD 0.41), but at very low certainty, and "safety data on lemborexant were inconclusive" (De Crescenzo et al., Lancet 2022).
  • In Eisai's pivotal trials, lemborexant cut night-time wakefulness by about 13–25 minutes more than placebo. It also narrowly beat low-dose zolpidem on wakefulness in the second half of the night, by 6.7–8.0 minutes (SUNRISE-1, JAMA Netw Open 2019, FDA label).
  • FDA reviewers found "no clear evidence" that it works better than suvorexant, the orexin antagonist already on the market, and found the 10 mg dose "did not appear to be markedly more effective" than 5 mg for the group as a whole (FDA multidisciplinary review).
  • Main risks: next-day sleepiness, sleep paralysis, and a small excess of suicidal ideation (0.3–0.4% vs 0.2%). It also has important interactions: avoid it with moderate or strong CYP3A inhibitors and inducers, including St John's wort (FDA label).
  • Evidence grade: Moderate for short-term efficacy. Weak for long-term benefit and comparative safety. Every pivotal trial was funded and analysed by Eisai.

Independent evidence review · Prescription medicine

Lemborexant is the orexin antagonist that comes out best in the largest independent ranking of sleeping pills. Even so, its advantage is modest, its long-term evidence is rated very low certainty, and almost every trial behind it was designed, analysed and written up with its manufacturer, Eisai. Like every sleeping pill, it comes after cognitive behavioural therapy for insomnia (CBT-I) in the guidelines (European Insomnia Guideline 2023, ACP 2016). It is widely used in Japan, where Eisai calls it the "number one brand in the insomnia treatment market" (Eisai FY2025 report). It is unavailable in the UK.

Best evidence for short-term help falling asleep and staying asleep in adults, including people over 55
Main risks next-day sleepiness and balance problems at night, sleep paralysis, suicidal ideation, many CYP3A interactions
Key rule 5 mg start, 10 mg maximum, at least 7 hours in bed, no alcohol
Safety first
Lemborexant is a prescription-only, controlled (Schedule IV in the US) sleep medicine. Do not start it, stop it or change the dose without your prescriber. It can cause next-day sleepiness and impaired driving; the label cautions people taking 10 mg against next-day driving. Alcohol raises lemborexant levels and adds to impairment, so do not combine them. Opioids, benzodiazepines and other sedatives also add to its effects. If you notice worsening depression or thoughts of suicide, or if you sleep-walk or sleep-drive, seek urgent medical help. In an emergency, call your local emergency number (FDA label, section 5).

Table of contents

Evidence summary

Claim Evidence Source Funding / conflict Strength
Short-term efficacy vs other sleeping pills In a network meta-analysis of 154 double-blind RCTs, lemborexant beat placebo in acute treatment. It was one of two drugs with "a favorable profile". De Crescenzo et al., Lancet 2022 UK NIHR (public). First author a Boehringer Ingelheim employee; senior author runs Janssen trials of seltorexant, a rival orexin drug. Moderate
Long-term efficacy SMD 0.41 (95% CI 0.04–0.78) vs placebo in long-term treatment, very low certainty. Eisai's 12-month trial reported that benefits were maintained. De Crescenzo 2022; Yardley et al., Sleep Med 2021 The NMA is public; Yardley is Eisai-funded with Eisai-employed authors. Weak
Falling asleep and staying asleep in people aged 55+ (sleep-lab measures) In SUNRISE-1 (n=1,006), sleep efficiency improved by 7.1–8.0 percentage points and wake after sleep onset fell by 24–25 minutes more than placebo. Rosenberg et al., JAMA Netw Open 2019 Funded by Eisai, which took part in design, analysis and the decision to publish Moderate
Better than zolpidem Wake after sleep onset in the second half of the night fell by 6.7–8.0 minutes more than with zolpidem ER 6.25 mg. Only one month, only people aged 55+, and zolpidem at a fixed low dose. SUNRISE-1 Eisai-funded; Eisai statisticians analysed the data Weak
Better than suvorexant No head-to-head trial exists. The FDA found "no clear evidence" of greater benefit than the orexin antagonist already on the market. FDA review 2019 US regulator Insufficient
No next-morning driving impairment No statistically significant average impairment at 2.5–10 mg. The label still reports that "driving ability was impaired in some subjects taking DAYVIGO 10 mg". Vermeeren et al., Sleep 2019; FDA label Eisai funded the study and paid Maastricht University; editorial support funded by Eisai and Purdue Pharma Moderate
Narcolepsy-like side effects Across orexin antagonists, sleep paralysis RR 3.40 and excessive daytime sleepiness RR 2.15 vs placebo. On the lemborexant label, sleep paralysis occurred in 1.3–1.6% vs 0% on placebo. Na et al., Sleep 2024; FDA label Korean public grant; label Risk
Irregular sleep–wake rhythm in Alzheimer's disease A phase 2 trial with 62 patients showed some actigraphy improvements. This is exploratory only. Moline et al., J Prev Alz Dis 2021 Eisai-funded; Eisai-employed authors Insufficient

Independent evidence and credibility scorecard

Source Who funds it Country Independence tier (1–4) Credibility (A–D) Why it would tell the truth / residual bias
De Crescenzo et al., Lancet 2022 UK NIHR UK / Italy 1–2 A− It was pre-registered and searched regulator websites for unpublished data. Its lemborexant data still come from Eisai trials, and some authors have industry ties (one to a rival orexin programme).
FDA multidisciplinary review 2019 US government. About 77% of drug-review costs come from industry user fees (FDA PDUFA report). USA 2 A− The FDA had patient-level data, and its benefit–risk text is candid about the drug's limits. It can only assess what the company submits, and no advisory committee was held.
European Insomnia Guideline 2023 European Sleep Research Society; NIHR grant listed Pan-European 2 B A broad consensus of 44 authors. We could not verify author conflicts because the publisher blocked access.
Na 2024, Pan 2024, Araujo 2026, Rollo 2026 Korean public grant, or none declared Korea / China / Brazil / Italy 1 B Academic, with no sponsor. They pool trials that the companies ran.
SUNRISE-1, SUNRISE-2 Eisai Japan / USA (multinational sites) 4 B for data, C for framing The trials were registered, had placebo control, and one had an active comparator; the FDA reviewed them. Eisai designed and analysed them and paid for medical writers.
McElroy et al., driving meta-analysis 2021 Eisai (paid Datalytics) Australia 4 C "Eisai was involved with all stages". This is a manufacturer-commissioned review comparing its product with its competitors.
Eisai consolidated financial report FY2025 Eisai Japan 4 B for figures, D for claims Securities rules apply to the revenue numbers. Market-position statements are company claims.

What lemborexant is

Lemborexant is a dual orexin receptor antagonist (DORA) sold as Dayvigo. Eisai Co., Ltd., headquartered in Tokyo, describes it as its "in-house discovered orexin receptor antagonist" (Eisai, January 2020, Eisai, December 2019).

Approvals.

  • US: FDA approval of NDA 212028 is dated 20 December 2019 (FDA approval letter). At approval, Eisai said the drug would reach the market after scheduling by the US Drug Enforcement Administration (Eisai).
  • Japan: approved on 23 January 2020 (Eisai).
  • China: approved in May 2025 and launched in August 2025 (Eisai FY2025 report).
  • Elsewhere: Eisai's 12-month trial paper lists approvals in the US, Japan and Canada (Yardley et al., 2021).

US status: prescription only, and a Schedule IV controlled substance (label section 9). FDA records list only Eisai's own application, with no generic applications (openFDA).

UK and EU status: not licensed. The UK electronic Medicines Compendium has no lemborexant product (EMC). A 2024 review states that daridorexant is the only orexin antagonist approved by the European Medicines Agency (Actas Esp Psiquiatr 2024). The UK orexin option appraised by NICE is daridorexant (NICE TA922). We found no primary source explaining why lemborexant has no European licence, so we do not speculate.

How it works

Orexin A and B are brain peptides that sustain wakefulness. Lemborexant is a competitive antagonist at both orexin receptors (IC50 6.1 nM at OX1R and 2.6 nM at OX2R). Its major metabolite, M10, binds the receptors with "comparable affinity". Blocking orexin signalling "is thought to suppress wake drive" (label 12.1–12.2). This is a different route from benzodiazepines and Z-drugs such as zolpidem, which enhance GABA inhibition.

Because loss of orexin causes narcolepsy, blocking it can produce narcolepsy-like effects, which is why narcolepsy is a contraindication.

Pharmacokinetics (label 12.3):

  • Peak blood levels come 1–3 hours after a dose. A high-fat meal delays the peak by 2 hours.
  • The effective half-life is 17 hours at 5 mg and 19 hours at 10 mg. That is longer than suvorexant's (about 12 hours), which is one reason next-morning effects are monitored.
  • It is cleared mainly by CYP3A4.

What it is prescribed for

Licensed use (US): "treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance" (label section 1). There is no UK licence.

Where guidelines place it:

  • CBT-I comes first everywhere. The ACP makes a strong recommendation for CBT-I, and a weak one for adding drugs only after CBT-I fails (ACP 2016). The European guideline rates CBT-I first-line at grade A (Riemann et al., 2023). NICE calls CBT-I "the standard first treatment" (NICE TA922).
  • European guideline 2023: "Orexin receptor antagonists can be used for periods of up to 3 months or longer in some cases" (grade A), once CBT-I has not been effective enough (Riemann et al., 2023).
  • AASM 2017: this guideline predates lemborexant's approval and makes no recommendation on it. Its only orexin recommendation was a WEAK "suggest" for suvorexant (Sateia et al., 2017).
  • AASM 2026: suggests CBT-I plus medication over medication alone. It also suggests against adding medication to CBT-I compared with CBT-I alone. Both are conditional recommendations based on low-certainty evidence (Buysse et al., 2026).

What works and what does not

Use Verdict What the evidence shows
Falling asleep and staying asleep, up to 6 months Works Beat placebo in both pivotal trials, on patient diaries and on polysomnography (label 14.1).
Acute efficacy ranked against other hypnotics Works Among the drugs that beat placebo, with a "favorable profile" (Lancet NMA 2022).
Benefit beyond 6–12 months Mixed Maintained over 12 months in Eisai's trial, but only with a placebo arm for the first 6 months. The Lancet NMA rated it very low certainty (Yardley 2021).
Better than zolpidem Mixed Small advantage on late-night wakefulness in one company trial against low-dose zolpidem ER (SUNRISE-1).
Better than suvorexant or daridorexant Insufficient No head-to-head trials (FDA review).
Alzheimer's-related sleep–wake rhythm problems Insufficient Phase 2 proof-of-concept only (Moline 2021).
Delirium prevention in hospital Insufficient A class-level meta-analysis gives low-certainty evidence and found no credible drug-specific effect (de Oliveira et al., 2025).

Benefits by claim

SUNRISE-2: 6 months, patient diaries (label "Study 1")

SUNRISE-2 randomised 949 adults aged 18 or over to placebo, 5 mg or 10 mg for 6 months, followed by a further 6 months on active drug only (Kärppä et al., Sleep 2020). The FDA label reports the 6-month results (label Table 3):

  • Time to fall asleep (patient-reported): the geometric mean fell from about 43–45 minutes to 20.0 minutes (5 mg) and 19.2 minutes (10 mg), against 27.3 minutes on placebo. That is a treatment ratio of 0.7.
  • Sleep efficiency: +4.5 percentage points (5 mg) and +4.7 percentage points (10 mg) vs placebo.
  • Wake after sleep onset: −17.5 minutes (5 mg) and −12.7 minutes (10 mg) vs placebo.

Note that placebo patients also improved a lot: their time to fall asleep dropped from 45 to 27 minutes. That fits the independent finding that 63.56% of the drug response in hypnotic trials also appears on placebo (Winkler & Rief, Sleep 2015). In the 12-month extension, benefits seen at 6 months "were maintained at twelve months", with no evidence of rebound insomnia or withdrawal (Yardley et al., 2021).

SUNRISE-1: 1 month, sleep laboratory, people aged 55+ (label "Study 2")

SUNRISE-1 randomised 1,006 people (86.4% women, median age 63) to placebo, zolpidem ER 6.25 mg, or lemborexant 5 mg or 10 mg (Rosenberg et al., JAMA Netw Open 2019). At nights 29–30:

  • Latency to persistent sleep: treatment ratio vs placebo 0.77 (95% CI 0.67–0.89) at 5 mg and 0.72 (0.63–0.83) at 10 mg.
  • Sleep efficiency: +7.1% and +8.0% vs placebo.
  • Wake after sleep onset: −24.0 and −25.4 minutes vs placebo.
  • Against zolpidem: wake after sleep onset in the second half of the night was −6.7 minutes (5 mg) and −8.0 minutes (10 mg).

The authors list their own limitations: the trial ran only 1 month, and it used a "fixed, albeit age-appropriate and sex-appropriate, dose of zolpidem".

What the FDA concluded

The FDA recommended approval, and wrote that analyses "suggest that the benefits will be clinically meaningful to patients". It added three caveats (FDA multidisciplinary review):

  • "The 10-mg dose of lemborexant did not appear to be markedly more effective than the 5-mg dose at the group level."
  • "Efficacy plateaus after 10 mg."
  • "There was no clear evidence that lemborexant would provide greater benefit than the currently marketed orexin receptor antagonist."

The FDA did not convene an advisory committee, because the Division "did not identify questions or concerns requiring discussion".

Independent comparisons

In the Lancet 2022 network meta-analysis, lemborexant was one of seven treatments that beat placebo acutely. For long-term treatment, only eszopiclone (SMD 0.63) and lemborexant (SMD 0.41, 95% CI 0.04–0.78) beat placebo, and both at very low certainty. The authors' summary was: "Overall, eszopiclone and lemborexant had a favorable profile, but eszopiclone might cause substantial adverse events and safety data on lemborexant were inconclusive" (De Crescenzo et al., 2022).

A 2026 meta-analysis of orexin antagonists in older adults found they improved sleep compared with placebo. It also found that "lemborexant and suvorexant were associated with higher rates of treatment-emergent adverse events than placebo, without an increase in serious adverse events", whereas daridorexant "showed a favorable safety profile" (Rollo et al., Sleep 2026).

Risks and all side effects

Dayvigo has no boxed warning. The label's warnings cover CNS depression and next-day impairment, sleep paralysis, hallucinations and cataplexy-like symptoms, complex sleep behaviours, compromised breathing, and worsening depression or suicidal ideation (label section 5).

Effect How often / detail Severity
Next-day impairment and driving It "can impair daytime wakefulness even when used as prescribed", and effects may persist "for up to several days" after stopping. "Driving ability was impaired in some subjects taking DAYVIGO 10 mg" (label 5.1, 14.2). High
Worsening depression / suicidal ideation Suicidal ideation or behaviour on questionnaire: 0.3% (10 mg), 0.4% (5 mg), 0.2% (placebo). The label says to prescribe the smallest feasible number of tablets (label 5.5). High
Complex sleep behaviours Two events in the trials, both at 10 mg. "Discontinue DAYVIGO immediately" if one occurs (label 5.3, 6.1). High
Night-time balance, attention and memory Healthy people aged 55+ woken 4 hours after a dose had impaired balance at 5 and 10 mg, and dose-dependent worsening of attention and memory. Ability to wake to sound was not affected (label 14.2). Moderate
Somnolence / fatigue First 30 days: 9.6% (10 mg), 6.9% (5 mg), 1.3% (placebo). In SUNRISE-2 over 6 months: 13.1%, 8.6% and 1.6%. In people aged 65+ on 10 mg: 9.8% (label 6.1, 8.5; Kärppä 2020). Moderate
Sleep paralysis and hypnagogic hallucinations Sleep paralysis: 1.6% (10 mg), 1.3% (5 mg), 0% (placebo). Hypnagogic hallucinations: 0.7%, 0.1%, 0%. Cataplexy-like leg weakness is possible (label 5.2, 6.1). Moderate
Nightmares / abnormal dreams 2.2% at 10 mg vs 0.9% on placebo. Nightmares were among the leading reasons for stopping (label 6.1). Moderate
Falls in older people The label warns of higher fall risk, particularly in elderly people. A meta-analysis found no significant increase in falls with orexin antagonists but notes that "the data for lemborexant and daridorexant are limited" (Pan et al., 2024). Moderate
Headache 5.9% (5 mg), 4.5% (10 mg), 3.4% (placebo) (label Table 1). Mild
Stopping because of side effects Over 6 months: 8.3% (10 mg), 4.1% (5 mg), 3.8% (placebo). Leading reasons were somnolence, nightmares and palpitations (label 6.1). —

Breathing. Unlike suvorexant, lemborexant was studied in mild and in moderate-to-severe obstructive sleep apnoea, and in moderate-to-severe COPD, for 8 nights at 10 mg. No clear worsening was seen. However, "clinically meaningful respiratory effects... cannot be excluded, including for long-term treatment" (label 8.8).

Dependence, abuse and withdrawal.

  • Lemborexant is Schedule IV in the US.
  • In recreational sedative users, 10–30 mg produced "Drug Liking" responses statistically similar to zolpidem 30 mg and suvorexant 40 mg.
  • Trials found no withdrawal signs on stopping, and no rebound insomnia (label 9, 14.2).

Source: FDA label. These findings come from trials of up to 12 months.

Regulators outside the US. Lemborexant is not authorised in the UK or EU, so there are no MHRA or EMA safety communications specific to it.

All interactions

Lemborexant's label is stricter on interactions than suvorexant's: it says to avoid moderate as well as strong CYP3A inhibitors (label sections 2.2 and 7).

Interacting drug or substance Examples (from the label) Effect Label action
Strong and moderate CYP3A inhibitors Itraconazole, clarithromycin (strong); fluconazole, verapamil (moderate) Higher lemborexant levels and more side effects Avoid
Strong and moderate CYP3A inducers Rifampin, carbamazepine, St John's wort (strong); bosentan, efavirenz, etravirine, modafinil (moderate) Lower lemborexant levels; may not work Avoid
Alcohol Any alcoholic drink Raises lemborexant exposure; worse balance and memory than alcohol alone Avoid
Other CNS depressants Benzodiazepines, opioids, tricyclic antidepressants, other sleeping pills Additive sedation and daytime impairment Dose adjustment may be needed; use with other insomnia drugs not recommended
Weak CYP3A inhibitors Chlorzoxazone, ranitidine Raised levels (less than 2-fold predicted) Maximum 5 mg
CYP2B6 substrates Bupropion, methadone Lemborexant lowers their levels and may reduce their effect Monitor response; a dose increase may be considered

The St John's wort interaction matters because the herb is sold over the counter. See our St John's wort review. Check any supplement with a pharmacist.

Who should avoid lemborexant

  • People with narcolepsy: this is the label's only formal contraindication (label section 4).
  • Severe liver impairment: not recommended. In moderate impairment the maximum is 5 mg. People with mild impairment or severe kidney impairment have higher exposure and may be at higher risk of somnolence, although no dose change is required for kidney impairment (label 2.3, 8.6–8.7).
  • People with depression or suicidal thoughts: the label advises careful and immediate evaluation of new behavioural signs. The FDA review notes that people with suicidal ideation or significant depression or anxiety scores were excluded from the trials (FDA review).
  • People with a history of substance misuse: the label says to follow them carefully (label 9.2).
  • Pregnancy: "There are no available data" in pregnant women. A US pregnancy registry exists. Animal studies showed effects only at high multiples of the human dose (label 8.1).
  • Breastfeeding: lemborexant passes into milk at a relative infant dose below 2%. Infants "should be monitored for excessive sedation" (label 8.2).
  • Older adults: "Exercise caution when using doses higher than 5 mg in patients ≥65 years old" (label 8.5). We could not confirm from the sources we accessed how the 2023 AGS Beers Criteria rate orexin antagonists.
  • Children: safety and effectiveness have not been established (label 8.4).

Dosage and how to take it

Your prescriber sets the dose. The official US adult dosing is summarised below for reference only (label section 2):

  • Recommended dose: 5 mg, no more than once a night, taken immediately before going to bed, with at least 7 hours before the planned wake time.
  • Maximum: 10 mg once nightly, "based on clinical response and tolerability".
  • With weak CYP3A inhibitors: maximum 5 mg. Avoid with strong or moderate inhibitors, and with strong or moderate inducers.
  • Moderate liver impairment: maximum 5 mg. Not recommended in severe impairment.
  • Food: taking it with or soon after a meal may delay sleep onset.

How long before it works: the label says effects at the start of treatment were "generally consistent with later timepoints". If insomnia persists after 7–10 days, the label advises re-evaluation for another medical or psychiatric cause (label 5.6, 14.1).

How to stop: in Eisai's trials there was no rebound insomnia and no withdrawal effects after stopping at either dose (label 14.2). Stopping should still be planned with your prescriber, especially after long use or if you take other sedatives.

Follow the money: who makes it and who funded the evidence

Originator and owner. Eisai Co., Ltd. (Tokyo, Japan) discovered, developed, owns and markets lemborexant. The US label is held by Eisai Inc. (Eisai, DailyMed). There are no US generics (openFDA).

Revenue. Eisai's consolidated report for the fiscal year to March 2026 gives these figures (Eisai consolidated financial report FY2025):

  • Worldwide Dayvigo revenue: ¥64.3 billion, up 19.6% on the year.
  • Japan: ¥46.5 billion, up 4.4%.
  • Americas: ¥10.5 billion, up 53.5%.
  • Forecast for the following year: ¥73.5 billion.

Eisai describes Dayvigo as "the number one brand in the insomnia treatment market in Japan". It says its new orexin-2 receptor agonist, E2086, now in trials for narcolepsy, was created by "leveraging our proprietary orexin platform acquired through the development of" Dayvigo. For comparison, Merck's rival Belsomra sold $186 million worldwide in 2025 (Merck 10-K).

Who paid for the evidence.

  • SUNRISE-1: "This study was funded by Eisai". Eisai "participated in the design and conduct of the study; data collection, data management, data analysis, and data interpretation; preparation, review, and approval of the manuscript; and the decision to submit". Data were "analyzed by statisticians employed by Eisai Inc". The first author reported grants from Eisai, Merck, Idorsia and Vanda outside the submitted work (Rosenberg et al., 2019).
  • SUNRISE-2: "financially supported by Eisai Inc... the owner and manufacturer of lemborexant". Several authors were Eisai employees, and one holds related patents. Eisai paid for the medical writing (Envision Pharma) (Kärppä et al., 2020). The 12-month extension paper was also written with Eisai employees (Yardley et al., 2021).
  • Driving study: Eisai funded the study and paid Maastricht University to run it. Editorial support "was funded by Eisai, Inc. and Purdue Pharma LP" (Vermeeren et al., 2019). The fetched sources do not explain Purdue Pharma's commercial role, and we do not speculate.
  • Driving meta-analysis: this review, which favourably compares lemborexant with rivals, was "funded by Eisai Inc., and Eisai was involved with all stages of the study conduct and analysis" (McElroy et al., 2021).
  • Alzheimer's rhythm trial: Eisai-funded, with Eisai-employed authors (Moline et al., 2021).
  • Independent sources: the NIHR-funded Lancet network meta-analysis (De Crescenzo 2022), the Korean-government-funded safety meta-analysis (Na 2024), and academic meta-analyses declaring no conflicts (Pan 2024, Araujo 2026, Rollo 2026).

Guideline and society conflicts.

  • The lead author of the AASM 2026 combination-therapy guideline has been a consultant for Eisai since 2019 and for Idorsia since 2021. Another author consulted for Eisai in 2021–2022 (Buysse et al., 2026).
  • The AASM's own company-support disclosure lists Eisai among its industry supporters (AASM disclosure).
  • The Lancet NMA that ranked lemborexant favourably was publicly funded. Its first author was a Boehringer Ingelheim employee, and its senior author leads Janssen trials of a competing orexin drug, seltorexant (De Crescenzo 2022).

The regulator. About 77% of FDA human-drug review costs were paid by industry user fees in FY2025 (FDA PDUFA report). We found no documented regulatory integrity event (fine, warning letter or data-misconduct finding) involving lemborexant in the sources reviewed.

Frequently asked questions

How long does lemborexant take to work?

Peak blood levels come 1–3 hours after a dose, and a heavy meal delays this by about 2 hours. That is why the label says to take it immediately before bed. Trial effects at the start of treatment were generally consistent with later time points. If insomnia persists after 7–10 days, the label advises re-evaluation (FDA label).

Can you drink alcohol on Dayvigo?

No. Alcohol increases lemborexant blood levels, and the combination worsened balance and memory more than alcohol alone. The label says to "avoid alcohol consumption with DAYVIGO" (FDA label 7.1).

Can I drive the next morning?

In the Eisai-funded on-road study, average next-morning driving was not significantly impaired at up to 10 mg. The label nonetheless says driving was impaired in some people on 10 mg, and cautions 10 mg users about next-morning driving. Taking it with less than a full night's sleep ahead raises the risk (Vermeeren et al., 2019, FDA label).

Is lemborexant better than suvorexant?

No trial has compared them directly. The FDA found "no clear evidence" that lemborexant provides greater benefit than suvorexant. Lemborexant has a longer half-life (17–19 hours vs about 12), and its label is stricter on CYP3A interactions. The Lancet 2022 network meta-analysis ranked lemborexant more favourably, but at low or very low certainty for several outcomes (FDA review, De Crescenzo 2022). See our suvorexant review.

How do I stop lemborexant safely?

Talk to your prescriber. In the 1-month and 12-month trials there was no rebound insomnia and no withdrawal effects after stopping (FDA label 14.2, Yardley 2021). Planning the stop with your prescriber still matters, particularly if you also take other sedatives.

Does lemborexant cause weight gain?

Weight gain is not listed among the adverse reactions in the US label. The common reactions are somnolence or fatigue, headache and nightmares or abnormal dreams. We found no independent study reporting weight gain (FDA label 6.1).

Is lemborexant addictive?

It is a Schedule IV controlled substance in the US. In people with a history of recreational sedative use, it produced "drug liking" similar to zolpidem and suvorexant. Clinical and animal studies did not show physical dependence or withdrawal (FDA label section 9).

Can I get Dayvigo in the UK?

No. It is not licensed in the UK and has no UK Medicines Compendium listing. The orexin antagonist available on the NHS is daridorexant, which NICE recommends only when CBT-I has not worked, is unavailable or is unsuitable (EMC, NICE TA922).

Sources and funding notes

Last reviewed: 26 September 2026. Educational information from Pure City Research, not medical advice. Medicine decisions belong with a qualified prescriber.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.